Breaks Categories: News

FridayNov 11, 2016 1:13 pm

Genocea Biosciences, Inc. (GNCA): ATLAS™ Study Demonstrates Potential for Personalized Cancer Vaccines; Shares Climb

Genocea Biosciences (NASDAQ: GNCA) is trading higher after the developer of cell-directed vaccines and immunotherapies reported data supporting the potential of its proprietary antigen identification screening system, ATLAS™, to identify personalized neoantigens that could guide development of neoantigen vaccines. Conducted in collaboration with Memorial Sloan Kettering Cancer Center (MSK), the study analyzed neoantigens in one non-small cell lung cancer patient successfully treated with pembrolizumab (KEYTRUDA®). Data will be presented at the Society for Immunotherapy of Cancer’s (SITC) 31st Annual Meeting & Associated Programs on November 12, 2016. To view the full press release, visit: http://nnw.fm/op5sS About Genocea Genocea is harnessing…

Continue Reading

WednesdayNov 09, 2016 10:17 am

Bristol-Myers Squibb Company (BMY), Infinity Pharmaceuticals, Inc. (INFI) Team Up to Evaluate Combination in Solid Tumors Study; Shares Jump

Shares of Bristol-Myers Squibb (NYSE: BMY) and Infinity Pharmaceuticals (NASDAQ: INFI) are higher after the companies announced their clinical trial collaboration to evaluate Bristol-Myers Squibb’s Opdivo in combination with Infinity’s IPI-549 in patients with advanced solid tumors. The dose-escalation portion exploring IPI-549 as a monotherapy in Infinity’s phase 1 study is continuing, and the first dose-escalation cohort studying IPI-549 in combination with Opdivo, a PD-1 immune checkpoint inhibitor, is scheduled to begin this fall. To view the full press release, visit: http://nnw.fm/V4tfN About Infinity Pharmaceuticals, Inc. Infinity is an innovative biopharmaceutical company dedicated to advancing novel medicines for people with…

Continue Reading

TuesdayNov 08, 2016 1:39 pm

Great Basin Scientific, Inc. (GBSN) Finishes Trial for Stool Bacterial Pathogens Panel; Shares Lower

Great Basin Scientific (OTCQB: GBSN) this morning reported the completion of its clinical trial of Stool Bacterial Pathogens Panel, a technology designed to detect Salmonella species, Shigella species, Shiga Toxin-producing E. coli species (stx1 and stx 2, O157), and Camphylobacter species (C. jejuni and C. coli). From here Great Basin intends to pursue 510(k) clearance from the Food and Drug Administration (FDA) as well as CE marking. To view the full press release, visit: http://nnw.fm/t5AgC About Great Basin Scientific Great Basin Scientific is a molecular diagnostics company that commercializes breakthrough chip-based technologies.  The Company is dedicated to the development of…

Continue Reading

TuesdayNov 08, 2016 10:50 am

ChromaDex Corp. (CDXC) Shares Tick Higher on $5M Credit Facility

ChromaDex (NASDAQ: CDXC) is trading higher this morning after announcing its $5 million credit facility with Bridge Bank. ChromaDex innovates proprietary health, wellness and nutritional ingredients that create science-based solutions to dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products. The company says the credit facility provides the capital needed to expand its proprietary ingredient business. To view the full press release, visit: http://nnw.fm/9joXj About ChromaDex: ChromaDex leverages its complementary business units to discover, acquire, develop and commercialize patented and proprietary ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets. In addition…

Continue Reading

TuesdayNov 08, 2016 10:47 am

Orexigen Therapeutics, Inc. (OREX) Inks Deal with Valeant Pharmaceuticals to Commercialize Contrave Weight Loss Drug; Shares Soar

Shares of Orexigen Therapeutics (NASDAQ: OREX) jumped more than 27% in morning trade after the company announced that its wholly owned subsidiary, Orexigen Therapeutics Ireland Ltd., will work with Valeant Pharmaceuticals International, Inc. to commercialize Orexigen’s weight loss drug, Contrave®,  in Australia and New Zealand. Per the agreement, Valeant will be responsible for obtaining regulatory approvals and for all commercialization activities; Orexigen will supply Contrave tablets to Valeant for an agreed transfer price and certain potential sales milestone payments. Orexigen said it expects Valeant to file for regulatory approvals in both countries in the first half of 2017. To view…

Continue Reading

FridayNov 04, 2016 11:16 am

FuelCell Energy, Inc. (FCEL) Installs 5.6MW Power Plant for Pfizer; Shares Climb

Shares of FuelCell Energy (NASDAQ: FCEL) are higher after the company said it has completed the construction and commercial operations of a previously announced 5.6 megawatt fuel cell project on Pfizer, Inc.’s (NYSE: PFE) R&D facility in Groton, Connecticut. The project is part of a 20-year power purchase agreement between a FuelCell subsidiary and Pfizer. To view the full press release, visit:  http://nnw.fm/jAhU4 About FuelCell Energy Direct FuelCell® power plants are generating ultra-clean, efficient and reliable power on three continents, affordably providing continuous distributed power generation to a variety of industries including utilities, commercial and municipal customers.  The Company’s power…

Continue Reading

FridayNov 04, 2016 11:14 am

Clean Diesel Technologies, Inc. (CDTI) to Raise $10.3M in Private Placement; Shares Lower

Clean Diesel Technologies (NASDAQ: CDTI) shares tumbled in morning trade after the company announced its plans to raise about $10.3 million in a private placement of common stock priced at $2 per share. “Together with the successful repositioning of the company and the elimination of approximately $8.9 million in debt in August, this financing supports our continued execution of our advanced materials business strategy by providing us a stronger financial foundation. This financing also represents a key milestone as we seek to achieve scale and profitability, as well as build long-term shareholder value,” company CEO Matthew Beale stated in the…

Continue Reading

FridayNov 04, 2016 11:12 am

MGT Capital Investments, Inc. (MGTI) to Acquire Technology Interests, Forego Appeal of NYSE Listing Decision

Shares of MGT Capital Investments, Inc. (OTC: MGTI) are higher after the company announced its plans to proceed its Asset Purchase Agreement for D-Vasive, which includes the acquisition of Demonsaw, rather than appealing the decision of the NYSE to delist MGT's common stock. “This decision is based on our belief that an appeal would have little likelihood of success given the lack of transparency the NYSE provided prior to the appeal deadline,” MGT stated in the news release. Upon closing of the deal, the company said it expects to be listed on OTCQB; John McAfee and Eric "Eijah" Anderson will…

Continue Reading

ThursdayNov 03, 2016 2:30 pm

Alternet Systems, Inc. (ALYI) Inks LOI with North American Cannabis Holdings, Inc. (USMJ), Aims for Cannabis Retail Payment System

Shares of Alternet Systems, Inc. (OTC: ALYI) are trading higher after North American Cannabis Holdings, Inc. (OTC: USMJ) announced a Letter of Intent between the two companies, with an end goal of bringing a cannabis retail payment system to market. The LOI is the initial advancement toward a “comprehensive contract” under which Alternet would acquire select assets from North American Cannabis Holdings, potentially enabling Alternet to leverage its financial software industry experience and introduce a cannabis retail payment system. To view the full press release, visit:  http://nnw.fm/i3iLZ About Alternet Systems, Inc. Alternet Systems, Inc. (ALYI) invests in innovative ways to…

Continue Reading

ThursdayNov 03, 2016 11:29 am

Curis, Inc. (CRIS) Posts Wider Q3 Loss; Shares Higher

Shares of Curis (NASDAQ: CRIS) this morning posted a third quarter net loss of $28.3 million, or $(0.21) per share, on revenues of $1.8 million vs. a net loss of $5.5 million, or $(0.04) per share, on revenues of $2.0 million for the third quarter of 2015. The net loss for the 2016 quarter includes a non-cash in-process research and development charge of $18.0 million related to the amendment of Curis's license agreement with Aurigene. To view the full press release, visit: http://nnw.fm/3uHzF About Curis, Inc. Curis is a biotechnology company focused on the development and commercialization of innovative and…

Continue Reading